Angioimmunoblastic T-Cell Lymphoma Medication

Updated: Apr 24, 2020
  • Author: Amira M Elbendary, MBBCh, MSc; Chief Editor: Dirk M Elston, MD  more...
  • Print
Medication

Medication Summary

Many agents have been used to treat angioimmunoblastic T-cell lymphoma (AITL), but none has proved universally or consistently effective. The dosing regimens of these treatments have not been definitively set. 

In 2018, the US Food and Drug Administration approved brentuximab vedotin for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCLs), including AITL and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP). [53]  

Next:

Antineoplastics, Anti-CD30 Monoclonal Antibodies

Class Summary

Antibody conjugate binds to cells expressing the CD30 antigen and forms a complex that is internalized within the cell and monomethyl auristatin E (MMAE) is released; MMAE induces cell cycle (G2/M phase) arrest by binding to tubules and disrupting the cellular microtubule network.

Brentuximab vedotin (Adcetris)

Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of chimeric IgG1 antibody cAC10, specific for human CD30 and the microtubule disrupting agent, MMAE, or vedotin. It is indicated for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing PTCLs, including AITL and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Previous